The study, with targeted enrollment of 211 patients at approximately 40 trial centers in the US and Europe, is designed to establish the safety and effectiveness of Troxatyl in patients with relapsed or refractory acute myelogenous leukemia (AML).
Dr Francis Giles of the department of leukemia at the University of Texas M.D. Anderson Cancer Center, and principal investigator in the study commented, “Our initial clinical studies and additional recent work with this novel investigational agent have demonstrated considerable promise for treatment of both AML and myelodysplastic syndromes, for which there are significant unmet medical needs. Among those needs, none are more pressing than in third-line treatment of AML”.
Troxatyl, a nucleoside analog, represents the first member of a new class of anticancer agents. Its unique chemical structure confers potential advantages compared to existing AML therapy in that it is not subject to common deactivating mechanisms that can cause resistance to existing therapy.